[{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0.32000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.32000000000000001,"dosageForm":"Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ CBC Group"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azilsartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HUNGARY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gedeon Richter \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gedeon Richter \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Azilsartan

Azilsartan
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Azilsartan

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

63 API Suppliers, 20 USDMF, 10 JDMF, 4 EU WC, 20 KDMF, 7 NDC API, 35 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

29 Drugs in Development

29 Drugs in Development

INTERMEDIATES

36 Intermediate Suppliers

36 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

38 FDF Dossiers, 11 FDA Orange Book, 16 Europe, 6 Canada, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 40MG MEDOXOMIL, TABLET;ORAL - EQ 80MG MEDOXOMIL, TABLET;ORAL - EQ 40MG MEDOXOMIL;12.5MG, TABLET;ORAL - EQ 40MG MEDOXOMIL;25MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 5 DKSH, 4 Gangwal Healthcare, 1 Pfanstiehl, 1 ACG Worldwide, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 10 Corel Pharma Chem, 3 DFE Pharma, 5 Gangwal Chemicals, 4 Ideal Cures, 2 Ingredion Pharma Solutions, 11 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 13 Roquette, 7 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Coating Systems & Additives, 39 Fillers, Diluents & Binders, 19 Direct Compression, 18 Disintegrants & Superdisintegrants, 15 Controlled & Modified Release, 15 Chewable & Orodispersible Aids, 13 Taste Masking, 12 Thickeners and Stabilizers, 12 Granulation, 11 Lubricants & Glidants, 9 Co-Processed Excipients, 6 Film Formers & Plasticizers, 5 Rheology Modifiers, 5 Empty Capsules, 5 Coloring Agents, 4 Parenteral, 4 Vegetarian Capsules, 3 API Stability Enhancers, 2 Solubilizers, 2 Emulsifying Agents

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 17 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 10 Regulatory FDF Prices, 9 Annual Reports

MARKET PLACE

19 APIs

19 APIs

PATENTS & EXCLUSIVITIES

16 US Patents, 16 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 USP, 10 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Lee Pharma

India

CPhI WW Frankfurt

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Lead Product(s) : Azilsartan

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Zhaoke (Guangzhou) Pharmaceutical Limited

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 29, 2018

Lead Product(s) : Azilsartan

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Zhaoke (Guangzhou) Pharmaceutical Limited

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Lee Pharma

India

CPhI WW Frankfurt

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Lead Product(s) : Azilsartan

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 30, 2016

Lead Product(s) : Azilsartan

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Lee Pharma

India

CPhI WW Frankfurt

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Lead Product(s) : Azilsartan

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 20, 2015

Lead Product(s) : Azilsartan

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Gedeon Richter

Hungary

Cell Therapy

Not Confirmed

05

Celltrion

South Korea

Cell Therapy

Not Confirmed

06

Zydus Lifesciences

India

Cell Therapy

Not Confirmed

07

Zydus Lifesciences

India

Cell Therapy

Not Confirmed

08

Celltrion

South Korea

Cell Therapy

Not Confirmed

09

Hasten Biopharmaceutic

China

Cell Therapy

Not Confirmed

10

Takeda Pharmaceutical

Japan

Cell Therapy

Not Confirmed

1
2
3